ENS@T-CANCER: Advancing Research on Adrenal Carcinomas
Patients diagnosed with adrenal masses, including adrenocortical carcinoma (ACC) and malignant pheochromocytomas (MPH), face a challenging medical scenario characterized by both low incidence rates and poor prognosis. These rare tumors, coupled with their concurrent hormone dysregulation and limited treatment options, exert a significant and adverse impact on affected individuals.
However, the rarity of ACC and MPH also presents obstacles for clinical research. Studies in this field often suffer from fragmentation and limited cohort sizes, making it difficult to draw robust conclusions.
The European Network for the Study of Adrenal Tumors (ENSAT), accessible at http://www.ensat.org, has taken significant strides in addressing these challenges. ENSAT has recently established a collection of databases focused on adrenal tumors and has formed a network of Biological Resource Centers dedicated to research in this field.